

## **Dennis Michael Williams**

Office: School of Pharmacy  
Kerr Hall CB# 7569, Room 3214  
University of North Carolina  
Chapel Hill, North Carolina 27599-7360  
Office: (919) 962-7122  
Fax: (919) 962-0644

### ***Education***

August 1974 – December 1981	University of Kentucky College of Pharmacy Pharm D.
August 1974 – May 1977	B.S. Pharmacy

### ***Professional Experience***

September 2008- June 2019	Vice Chair, Professional Education and Practice Division of Pharmacotherapy and Experimental Therapeutics
November 2000- Present	Associate Professor Division of Pharmacotherapy and Experimental Therapeut School of Pharmacy University of North Carolina
October 1993 – October 2000	Assistant Professor School of Pharmacy University of North Carolina
March 1990 -November 1995	Vice Chairman for Professional Education of Pharmacy Practice School of Pharmacy University of North Carolina
December 1985 - Present	Clinical Specialist, Pulmonary Medicine UNC Hospitals
August 1991 - September 1993	Clinical Associate Professor School of Pharmacy University of North Carolina
June 1977 – June 1978	Instructor Division of Community Pharmacy and Pharmacy Administration University of Kentucky College of Pharmacy Lexington, Kentucky
June 1978 – May 1980	Clinical Pharmacist Eastern Kentucky Health Services Center Inc. Hindman, Kentucky

May 1980 – July 1982	Staff Pharmacist University of Kentucky Medical Center Lexington, Kentucky
August 1982 - July 1983	Associate Director, Pharmacy Activities Health Education Foundation of Eastern North Carolina, Inc. Tarboro, North Carolina
August 1983 - November 1985	Director of Pharmacy (9/84 - 11/85) Project Pharmacist (3/84 - 8/84) Clinic Pharmacist (8/83 - 3/84) Orange-Chatham Comprehensive Health Services, Inc. 400 Roberson Street Carrboro, North Carolina
August 1983 - July 1991	Clinical Assistant Professor School of Pharmacy University of North Carolina Chapel Hill, North Carolina

***Honors***

American Pharmacists Association Bowl of Hygeia Award 2019

Overall Instructor of the Year, UNC ESOP Class of 2018

Honorary Residency Certificate, Department of Pharmacy, UNC Medical Center 2017

Overall Instructor of the Year, UNC ESOP Class of 2017

Allergy and Asthma Network Service Award 2015

Carolina Association of Pharmacy Students Recognition Award 2014

North Carolina Association of Pharmacists President’s Service Award 2014

Outstanding Faculty Award, PY2 Class, 2012 – Class of 2014

Selected as Speaker, White Coat Ceremony 2013 (Class of 2014)

Outstanding Faculty Award (overall) Class of 2012

Selected as ‘Coater’ for White Coat Ceremony for UNC Students Classes of 2006-2009, 2012, 2014-20

Served as ‘Hooder’ at Graduation and Recognition Ceremony for UNC Students Class of 2006-2009, 2012, 2017, 2018

Fellow, Academy of Pharmacy Practice and Management (APPM), APhA (FAPhA) 1999

APhA Academy of Pharmacy Practice and Management (APPM) Presentation Merit Award for “Smoking Cessation Activities by Pharmacists”. March 22, 1998

APhA-APPM Distinguished Achievement Award in Clinical/Pharmacotherapeutic Practice, 1998.

Fellow, American College of Clinical Pharmacy (FCCP), 1994.

Fellow, American Society of Hospital Pharmacists (FASHP), 1994.

APhA-ASP Outstanding Chapter Advisor Award, 1992

NCSHP Continuing Excellence Award 1992, 1991, 1990, 1989, 1988

Co-Recipient, Upjohn Research Award: NCSHP 1988

Who's Who in The South and Southwest, 1987, 21st Edition

Certificate of Appreciation, Barren-Green River AHES - 1978

McKesson Robbins Scholarship Award - 1977

Rho Chi Service Award - 1977

Omicron Delta Kappa National Leadership Honorary - 1977

Lilly Achievement Award - 1977

Who's Who in American Colleges and Universities - 1977

Jefferson County Academy of Pharmacy Award - 1976

### ***Professional Licensure and Certification***

September 2002

Certified Asthma Educator (AE-C)

August 1991

Board Certified Pharmacotherapy Specialist #291138  
(BCPS) 1991-1997, Recertified in 1998, 2006 and 2014

March 1983

North Carolina License #8312

July 1977

Kentucky License #7863

### ***Book Chapters/Case Workbooks/NIH Documents***

1. Bourdet S, Williams DM. Chronic Obstructive Pulmonary Disease. In: Pharmacotherapy: A Pathophysiologic Approach, 11<sup>th</sup> Edition 2019. Haines S, et al. Editors. McGraw Hill Medical. New York (In Press)
2. Williams DM, Woodyard JLS. Allergic Rhinitis. PharmacotherapyFirst Online, 2019. American Pharmacists Association. Washington DC. Available at: [https://doi.org/10.21019/pharmacotherapyfirst.rhinitis\\_overview](https://doi.org/10.21019/pharmacotherapyfirst.rhinitis_overview)
3. Bourdet S, Williams DM. Chronic Obstructive Pulmonary Disease. In: Pharmacotherapy: A Pathophysiologic Approach, 10<sup>th</sup> Edition 2017. Dipiro JT, et al, Editors. McGraw Hill Medical. New York.

4. Bollmeier S, Williams DM. Chronic Rhinitis. In: Applied Therapeutics: The Clinical Use of Drugs. 11<sup>th</sup> Edition, 2017. Zeind CS and Carvalho M, Editors. Wolters Kluwer Health. Baltimore.
5. Bourdet S, Williams DM. Chronic Obstructive Pulmonary Disease. In: Pharmacotherapy: A Pathophysiologic Approach, 9th Edition 2014. DiPiro JT, et al, Editors. McGraw Hill Medical. New York.
6. Williams DM. Sexually Transmitted Infections. In: Infectious Diseases. Ambulatory Care Self-Assessment Program, Module 2. 2013. American College of Clinical Pharmacy 2013.
7. Williams DM (editor). Respiratory Conditions and Preventative Medicine. Ambulatory Care Self - assessment Program. Module 1, 2013. American College of Clinical Pharmacy 2013.
8. Brock TP, Williams DM. Acute and Chronic Rhinitis. In: Applied Therapeutics: The Clinical Use of Drugs. 10<sup>th</sup> Edition, 2013. Alldredge BK, et al, Editors. Lippincott, Williams and Wilkins. Philadelphia.
9. Williams DM, Bourdet S. Chronic Obstructive Pulmonary Disease. In: Pharmacotherapy: A Pathophysiologic Approach, 8th Edition 2011. DiPiro JT, et al, Editors. McGraw Hill Education. New York.
10. Brock TP, Williams DM. Allergic Rhinitis. Applied Therapeutics: The Clinical Use of Drugs. 9<sup>th</sup> Edition, 2008. Koda-Kimble MA et al, Editors. Lippincott, Williams and Wilkins. Philadelphia.
11. Williams DM, Bourdet S. Chronic Obstructive Pulmonary Disease. In. Pharmacotherapy: A Pathophysiologic Approach, 7th Edition 2008.
12. Williams DM, Self TH. Asthma. In: Handbook of Nonprescription Drugs, 14th Edition. Berardi RR et.al, Editors. American Pharmacists Association, Washington, DC. 2004.
13. Williams DM. Chronic Asthma. In: Pharmacotherapy Casebook, 6th edition. Swinghammer TL, editor. McGraw-Hill, Inc. New York. 2004.
14. McDonald A, Williams DM. Sexually Transmitted Diseases. In: Pharmacotherapy Casebook, 6th edition. Swinghammer TL, editor. McGraw-Hill, Inc. New York. 2004.
15. Brock TP, Williams DM. Pulmonary Tuberculosis. In: Pharmacotherapy Casebook, 6th edition. Swinghammer TL, editor. McGraw-Hill, Inc. New York. 2004.
16. Williams DM. Chronic Obstructive Pulmonary Disease. In: Applied Therapeutics: The Clinical Use of Drugs, 8th edition. Lippincott Williams & Wilkins. 2004.
17. Brock TP, Williams DM. Allergic Rhinitis. In: Applied Therapeutics: The Clinical Use of Drugs, 8th edition. Lippincott Williams & Wilkins. 2004.
18. Allergic Rhinitis and its Impact on Asthma Working Group. ARIA in the pharmacy: Management of allergic rhinitis symptoms in the pharmacy. Allergy 2004;59: 373-87. ([www.whear.com](http://www.whear.com))
19. Williams DM. The application of aerosolized antimicrobial therapies in lung infections. In: Pharmaceutical Inhalation Aerosol Technology, 2nd edition. Hickey AJ, editor. Marcel Dekker, Inc. New York 2004.
20. Williams DM, Self TH. Asthma. In: Handbook of Nonprescription Drugs, 13th edition. Berardi RR, DeSimone EM, Newton GD, et al, eds. American Pharmaceutical Association, Washington, DC. 2002.
21. Williams DM. Case Study: Chronic Asthma. In: Pharmacotherapy Casebook: A patient-focused approach. 5th Edition. Swinghammer TL, ed. McGraw-Hill. New York 2002: 87-9.

22. McDonald AK, Williams DM. Case Study: Syphilis. In: Pharmacotherapy Casebook: A patient-focused approach. 5th Edition. Schwinghammer TL, ed. McGraw-Hill. New York 2002: 322-23.
23. Brock TP, Williams DM. Pulmonary Tuberculosis. In: Pharmacotherapy Casebook: a patient-focused approach, 5th edition. 2002. Schwinghammer TL, Ed. McGraw-Hill. New York 2002: 307-9.
24. Shaefer S, Williams DM. Case Study: Pulmonary Tuberculosis. In: Pharmacotherapy Casebook: A patient-focused approach. 2nd Edition. Schwinghammer TL, Ed. McGraw-Hill. 2001.
25. McDonald AK, Williams DM. Case Study: Syphilis. In: Pharmacotherapy Casebook: A patient-focused approach. 2nd Edition. Schwinghammer TL, Ed. McGraw-Hill. 2001.
26. Williams DM. Case Study: Chronic Asthma. In: Pharmacotherapy Casebook: A patient-focused approach. 2nd Edition. Schwinghammer TL, Ed. McGraw-Hill. 2001.
27. Kradjan WA, Williams DM. Chronic Obstructive Pulmonary Disease. In: Applied Therapeutics, 7th edition. Koda-Kimble MA, Young LY, Eds. Lippincott Williams and Wilkins, Philadelphia 2001.
28. Williams DM. Asthma. In: Mueller BA, et al., Eds. Pharmacotherapy Self-Assessment Program, Fourth Edition. Kansas City, MO: American College of Clinical Pharmacy, 2001.
29. Williams DM. Respiratory Disease Protocols. In: Albrant DH, et al., eds. Drug Treatment Protocols, 2nd edition. American Pharmaceutical Association. Washington, DC 2001.
30. Williams DM, Self TH. Asthma. In: Handbook of Nonprescription Drugs, 12th edition. Allen LV, et al, eds. American Pharmaceutical Association, Washington, DC 2000. p. 215-39.
31. Williams DM. Section Editor (Infectious Diseases and Respiratory). PSAP Algorithms. Kansas City, MO: American College of Clinical Pharmacy, 2000.
32. Williams DM. Chronic obstructive pulmonary disease. In: Carter BL, et al., eds. Pharmacotherapy Self-Assessment Program, Third Edition. Kansas City, MO: American College of Clinical Pharmacy, 1999.
33. Williams DM. Case Study: Chronic Asthma. In: Pharmacotherapy Casebook: A patient-focused approach, 2nd Edition. Schwinghammer TL, ed. Appleton & Lange 1999.
34. McDonald A, Williams DM. Case Study: Syphilis In: Pharmacotherapy Casebook: A patient-focused approach, 2nd Edition. Schwinghammer TL, ed. Appleton & Lange 1999.
35. Shaffer S, Williams DM. Case Study: Pulmonary Tuberculosis In: Pharmacotherapy Casebook: A patient-focused approach, 2nd Edition. Schwinghammer TL, Edition. Appleton & Lange 1999.
36. Williams DM. Section Editor and Editorial Board. A Guide to Clinical Decision-Making: The PSAP Algorithms. American College of Clinical Pharmacy. Kansas City, MO. 1997.
37. NAEPP Working Group Report: Considerations for Diagnosing and Managing Asthma in the Elderly. NIH Publication No. 96-3662. February 1996.
38. Williams DM. Case Studies Workbook: Pharmacotherapy: Asthma, Tuberculosis, Sexually Transmitted Diseases. Pharmacotherapy: A patient-focused approach, 1st Edition. Schwinghammer TL, Ed. Appleton and Lange 1996.

39. Williams DM, Self TH. Asthma Products. In: Covington TR, Berardi RR, Young LL, Eds. Handbook of Nonprescription Drugs, 11th Edition. American Pharmaceutical Association, Washington, DC. 1996: 157-177.
40. The Role of the Pharmacist in Improving Asthma Care. NIH Publication No. 95-3280. July 1995. Also: Am J Health-Syst Pharm 1995; 52: 1411-16. and Amer Pharm 1995; NS35 (11): 24-29.
41. Williams DM. Chronic Obstructive Airways Disease. In: Applied Therapeutics, The Clinical Use of Drugs, 6th edition. Applied Therapeutics, Inc., Vancouver, WA . 1995. 20-1 to 20-12.
42. Bettenhausen D, Williams D. Gastrointestinal Disorders Cases 4 and 6. In: Handbook of Nonprescription Drugs Case Studies Workbook, 10th Edition. American Pharmaceutical Association, Washington DC 1993.

### ***Refereed Articles***

1. Bousquet J, Hellings PW, Agache I et al and MASK Study Group (Williams DM). Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Aller Clin Immunol 2019; 143(3):864-869.
2. Bousquet J, Bedbrook A, Czarlewski W and MASK Study Group (Williams DM). Guidance to 2018 Good Practice:ARIA digitally-enabled, integrated, patient centered care for rhinitis and asthma. Clin Transl Allergy 2019; 9:16-35.
3. Bosnic-Anticevich, Costa E, Menditto E, et al (Williams DM). Allergic rhinitis care pathways for community pharmacy. Allergy 2018 (Dec 18<sup>th</sup> online). doi.org/10.1111/all.13701.
4. Bousquet J, Arnavielhe S, Bedbrook A, and MASK Study Group (Williams DM). MASK 2017:ARIA digitally-enabled, integrated, patient centered care for rhinitis and asthma multimorbidity using real world evidence. Clin Transl Allergy 2018;8:45-66. doi: 10.1186/s13601-018-0227-6
5. Williams DM, Rubin B. Clinical pharmacology of bronchodilator medications. Respir Care 2018; 63(6):641-654.
6. Williams DM. Clinical pharmacology of corticosteroids. Respir Care 2018; 63(6):655-670.
7. Kufel WD, Jeffres M, MacDougall C, Cho JC, Marx AH, Williams DM. Antimicrobial stewardship education in US colleges and schools of pharmacy. J Antimicrobial Chemotherapy 2018; 73(8):2252-2258.
8. Forshay M, Williams DM. Opportunities for pharmacist involvement on medical missions. NC Pharmacist 2018; 99(1): 31-34.
9. Kufel WD, Williams DM, Weber DJ. Improving immunization practices in US hospitals and health systems. Intern J Health Governance 2017; 22(3): 199-211.
10. Rhodes LA, Williams DM, Marciniak MW, Weber DJ. Community pharmacists as vaccine providers. Intern J Health Governance 2017; 22(3): 167-182.
11. Pinelli NR, McLaughlin JE, Chen SL, Luter DN, Arnall J, Smith S, Roth MT, Rodgers PT, Williams DM, Amerine LB. Improved organizational outcomes associated with incorporation of early clinical experiences for second-year student pharmacists at an academic medical center. J Pharm Pract 2017 (Feb);30(1):99-108. DOI 10.1177/0897109915585765
12. Alsharif NZ, Dakkuri A, Abrons JP, Williams DM, Ombengi DN, Zheng H, Al-Dahir S, Tofade T, Gim S, O'Connell MB, Ratka A, Dornblaser E. Current practices in global/international advanced pharmacy

practice experiences: Home/host country or site/institution considerations. *Am J Pharm Educ* 2016;80(3):38. DOI 10.5688/ajpe80338

13. Bousquet J, Farrell J, Grook G, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing. *Clin Transl Allergy* 2016;6:29. DOI 10.1186/s13601-016-0116-9
14. Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy* 2016;6: 47. DOI 10.1186/s13601-016-0137-4
15. McLaughlin JE, Amerine LB, Chen SL, Luter DN, Arnall J, Smith S, Roth MT, Rodgers PT, Williams DM, and Pinelli NR. Early Clinical Experiences for Second-Year Student Pharmacists at an Academic Medical Center. *American Journal of Pharmaceutical Education* 2015; 79(9): Article 139. doi: 10.5688/ajpe799139
16. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, et al. MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. *Allergy*. 2015 Nov;70(11):1372-92. doi: 10.1111/all.12686. Epub 2015 Sep 13. PubMed PMID: 26148220.
17. Gillette C, Blalock SJ, Rao JK, Williams D, Loughlin C, Sleath B. Discussions between medical providers and children/caregivers about the benefits of asthma-control medications. *J Am Pharm Association*. 2014 May-Jun; 54(3):251-7. doi: 10.1331/JAPhA.2014.13097. PubMed PMID: 24816351.
18. Gillette C, Blalock SJ, Rao JK, Williams D, Loughlin CE, Sleath B. Provider-caregiver-child discussions about risks associated with asthma control medications: content and prevalence. *Pediatr Pulmonol*. 2014 Aug;49(8):727-33. doi: 10.1002/ppul.22892. Epub 2013 Sep 20. PubMed PMID: 24115531.
19. Ayala GX, Gillette C, Williams D, Davis S, Yeatts KB, Carpenter DM, Sleath B. A prospective examination of asthma symptom monitoring: provider, caregiver and pediatric patient influences on peak flow meter use. *J Asthma*. 2014Feb;51(1):84-90. doi: 10.3109/02770903.2013.838255. Epub 2013 Sep 19. PubMed PMID: 24020680.
20. Carpenter DM, Stover A, Slota C, Ayala GX, Yeatts K, Tudor G, Davis S, Williams D, Sleath B. An evaluation of physicians' engagement of children with asthma in treatment-related discussions. *J Child Health Care*. 2014 Sep;18(3):261-74. doi: 10.1177/1367493513489780. Epub 2013 Jun 30. PubMed PMID:23818146.
21. Sleath B, Carpenter DM, Beard A, Gillette C, Williams D, Tudor G, Ayala GX. Child and caregiver reported problems in using asthma medications and question-asking during pediatric asthma visits. *Int J Pharm Pract*. 2014Feb; 22(1):69-75. doi: 10.1111/ijpp.12043. Epub 2013 May 29. PubMed PMID:23718931; PubMed Central PMCID: PMC3868634.
22. Gillette C, Carpenter DM, Ayala GX, Williams DM, Davis S, Tudor G, Yeatts K, Sleath B. How often do providers discuss asthma action plans with children? Analysis of transcripts of medical visits. *Clin Pediatr (Phila)*. 2013 Dec;52(12):1161-7. doi: 10.1177/0009922813506256. Epub 2013 Oct 17. PubMed PMID: 24137029.
23. Ayala GX, Gillette C, Williams D, Davis S, Yeatts KB, Carpenter DM, Sleath B. A prospective examination of asthma symptom monitoring: provider, caregiver and pediatric patient influences on peak flow meter use. *J Asthma*. 2013 Sep 19. [Epub ahead of print] PubMed PMID: 24020680.

24. Carpenter DM, Stover A, Slota C, Ayala GX, Yeatts K, Tudor G, Davis S, Williams D, Sleath B. An evaluation of physicians' engagement of children with asthma in treatment-related discussions. *J Child Health Care*. 2013 Jun 30. [Epub ahead of print] PubMed PMID: 23818146.
25. Carpenter DM, Ayala GX, Williams DM, Yeatts KB, Davis S, Sleath B. The relationship between patient-provider communication and quality of life for children with asthma and their caregivers. *J Asthma*. 2013 Sep;50(7):791-8. doi:10.3109/02770903.2013.808347. Epub 2013 Jul 4. PubMed PMID: 23730868.
26. Sleath B, Carpenter DM, Beard A, Gillette C, Williams D, Tudor G, Ayala GX. Child and caregiver reported problems in using asthma medications and question-asking during paediatric asthma visits. *Int J Pharm Pract*. 2013 May 29. doi: 10.1111/ijpp.12043. [Epub ahead of print] PubMed PMID: 23718931.
27. Sleath B, Carpenter DM, Ayala GX, Williams D, Davis S, Tudor G, Yeatts K, Gillette C. Communication during pediatric asthma visits and child asthma medication device technique 1 month later. *J Asthma*. 2012 Nov;49(9):918-25. doi: 10.3109/02770903.2012.719250. Epub 2012 Sep 13. PubMed PMID: 22974226.
28. Sleath B, Carpenter DM, Slota C, Williams D, Tudor G, Yeatts K, Davis S, Ayala GX. Communication during pediatric asthma visits and self-reported asthma medication adherence. *Pediatrics*. 2012 Oct;130(4):627-33. doi:10.1542/peds.2012-0913. Epub 2012 Sep 3. PubMed PMID: 22945409; PubMed Central PMCID: PMC3457624.
29. Sleath BL, Carpenter DM, Sayner R, Ayala GX, Williams D, Davis S, Tudor G, Yeatts K. Child and caregiver involvement and shared decision-making during asthma pediatric visits. *J Asthma*. 2011 Dec;48(10):1022-31. doi:10.3109/02770903.2011.626482. Epub 2011 Oct 25. PubMed PMID: 22022958; PubMed Central PMCID: PMC3263821.
30. Sleath B, Carpenter DM, Ayala GX, Williams D, Davis S, Tudor G, Yeatts K, Gillette C. Provider Discussion, Education, and Question-Asking about Control Medications during Pediatric Asthma Visits. *Int J Pediatr*. 2011;2011:212160. doi:10.1155/2011/212160. Epub 2011 Aug 10. PubMed PMID: 21860627; PubMed Central PMCID: PMC3155790.
31. Gillette C, Loughlin CE, Sleath BL, Williams DM, Davis SD. Quality of pulmonary function testing in 3 large primary care pediatric clinics in rural North Carolina. *NC Med J*. 2011 Mar-Apr;72(2):105-10. PubMed PMID: 21721494.
32. Washington D, Yeatts K, Sleath B, Ayala GX, Gillette C, Williams D, Davis S, Tudor G. Communication and education about triggers and environmental control strategies during pediatric asthma visits. *Patient Educ Couns*. 2012 Jan;86(1):63-9. doi: 10.1016/j.pec.2011.04.015. Epub 2011 May 19. PubMed PMID:21600721; PubMed Central PMCID: PMC3168678.
33. Sleath B, Ayala GX, Gillette C, Williams D, Davis S, Tudor G, Yeatts K, Washington D. Provider demonstration and assessment of child device technique during pediatric asthma visits. *Pediatrics*. 2011 Apr;127(4):642-8. doi: 10.1542/peds.2010-1206. Epub 2011 Mar 28. PubMed PMID: 21444594; PubMed Central PMCID: PMC3065074.
34. Cataletto M, Abramson S, Meyerson K, Dennis R, Arney TD, Bollmeier S, Hargrove JK, Harver A, Williams D, Wissing D. The Certified Asthma Educator (AE-C): Opting for a Standard of Excellence in Asthma Care. *Journal of Asthma & Allergy Educators*, 2150129711432631, first published on January 20, 2012
35. Cataletto M, Abramson S, Meyerson K, Dennis R, Arney TD, Bollmeier S, Hargrove JK, Harver A, Wissing D, Williams D. The Certified Asthma Educator: The United States Experience. *Pediatric Allergy Immunology and Pulmonology* 2011; 24(3): 159-63.

36. Sleath B, Carpenter DM, Ayala GX, Williams D, Davis S, Tudor G, Yeatts K, Gillette C. Provider Discussion, Education, and Question-Asking about Control Medications during Pediatric Asthma Visits. *Int J Pediatr*. 2011;2011:212160. PMID: 21860627
37. Gillette C, Loughlin CE, Sleath BL, Williams DM, Davis SD. Quality of pulmonary function testing in 3 large primary care pediatric clinics in rural North Carolina. *North Carolina Medical Journal*. 2011;72(2):105-10. PMID: 21721494
38. Washington D, Yeatts K, Sleath B, Ayala GX, Gillette C, Williams D, Davis S, Tudor G. Communication and education about triggers and environmental control strategies during pediatric asthma visits. *Patient Education and Counseling*. 2011;86:63-69. PMID: 21600721
39. Sleath B, Ayala GX, Gillette C, Williams D, Davis S, Tudor G, Yeatts K, Washington D. Provider demonstration and assessment of child device technique during pediatric asthma visits. *Pediatrics*. 2011;127(4):642-8. PMID: 21444594
40. Sleath B, Ayala GX, Davis S, Williams D, Tudor G, Yeatts K, Washington D, Gillette C. Caregiver rating of provider participatory decision-making style and caregiver and child satisfaction with pediatric asthma visits. *Patient Education and Counseling*. 2011;85:286-289. PMID: 20971603
41. Sleath BL, Carpenter DM, Sayner R, Ayala GX, Williams D, Davis S, Tudor G, Yeatts K. Child and Caregiver Involvement and Shared Decision-Making during Asthma Pediatric visits. *Journal of Asthma*. 2011;48(10):1022-1031. PMID: 22022958
42. Sleath B, Ayala GX, Washington D, Davis S, Williams D, Tudor G, Yeatts K, Gillette C. Caregiver rating of provider participatory decision-making style and caregiver and child satisfaction with pediatric asthma visits. *Patient Educ Couns*. 2011 Nov;85(2):286-9. doi: 10.1016/j.pec.2010.09.016. Epub 2010 Oct 23. PubMed PMID: 20971603; PubMed Central PMCID: PMC3070191.
43. Sleath B, Ayala GX, Davis S, Williams D, Tudor G, Yeatts K, Washington D, Gillette C. Child- and caregiver-reported problems and concerns in using asthma medications. *J Asthma*. 2010 Aug; 47(6):633-8. doi: 0.3109/02770901003692785. PubMed PMID: 20632916.
44. Williams D. Long-acting  $\beta_2$  agonists for asthma: a clinical paradox. *Consult Pharm*. 2010; 25:756-9.
45. Sleath B, Ayala GX, Davis S, Williams D, Tudor G, Yeatts K, Washington D, Gillette C. Child and Caregiver: Reported Problems and Concerns in Using Asthma Medications. *J Asthma*. 2010;47(6):633-8. PMID: 20632916
46. Bousquet J, Schunemann HJ, Zuberbier T, et al. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. *Allergy* 2010; DOI:10.1111/j. 1398-9995.2010.02439.x.
47. Williams DM. Preparing pharmacy students and pharmacists to provide tobacco cessation counseling. *Drug Alcohol Rev* 2009;28:533-540.
48. Williams DM. Management of pediatric asthma: focus on Expert Panel Report 3. *J Pediatr Health Care* 2009;23:357-368.
49. Ueno M, Maehara K, Yoshizumi A, Ikeuchi T, Mashima K, Yamamoto T, Williams DM, Futagami K. Smoking cessation intervention program for inpatients conducted by pharmacists. *Jpn J Pharm Health Care Sci* 2008; 34(9): 882-90.

50. Washiyama A, Yamamoto T, Kinoshita S, Haji K, Wakita S, Inokuchi H, Kawahara Y, Ogata K, Hatano S, Williams DM, Futagami K. Establishment of a resident system for pharmacists at Fukuoka University Hospital and its assessment. *Jpn J Pharm Health Care Sci* 2008; 34(9): 853-9.
51. Brock TP, Williams DM. Readability of brochure related to phaseout of chlorofluorocarbon propellants. *Am J Health-System Pharmacy* 2006 (In Press)
52. Williams DM. What does potency mean for inhaled corticosteroids? *J Asthma* 2005;42:409-17.
53. Smyth HBC, Beck VP, Williams DM, Hickey AJ. The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers. *AAPS PharmSciTech* 2004;5(1):Article 7.
54. Brock TP, Wessell AM, Williams DM, Donohue JF. Accuracy of float testing for metered-dose inhaler (MDI) canisters. *Journal of the American Pharmaceutical Association* 2002;42(4): 582-6.
55. Brock TB, Faulkner CM, Williams DM, Smith SR. Continuing education programs in pharmacogenomics for pharmacists. *Am J Health-Syst Pharm* 2002;59:722-4.
56. Deaton AT, Jones LD, Dunbar CA, Hickey AJ, Williams DM. Generation of gelatin aerosol particles from nebulized solutions as model drug carrier systems. *Pharmaceutical Development and Technology* 2002;7(2):147-53.
57. Brock TB, Williams DM. Clinical considerations in the use of inhalation delivery devices. *J Pharm Pract* 2001;14(4):277-95.
58. Bourdet SV, Williams DM. Management considerations for chronic asthma. *J Pharm Pract* 2001;14(2):108-125.
59. Williams DM. Clinical considerations in the use of inhaled corticosteroids for asthma. *Pharmacotherapy* 2001;21(3 Pt 2):38s-48s.
60. Williams DM, Newsom JF, Brock TP. An evaluation of smoking cessation activities by pharmacists (ESCAP). *J Amer Phar Assoc* 2000;40:366-70.
61. Brock TP, Williams DM, Beauchesne MF. Assessment of the readability and comprehensibility of a CFC-transition brochure. *Ann All Asthma Immunol* 2000;84:211-14.
62. Williams DM, Beauchesne MF. Considerations in the long-term management of chronic asthma. *Home Health Care Consultant* 1999;6(6):11-23.
63. Toso C, Williams DM. Practice Pearls: Otitis Media with Effusion. *J Amer Pharm Assoc* 1996; NS36(9): 591-2.
64. Gray S, Williams DM, Pulliam C, Sirgo M, Bishop A, Donohue JF. Characteristic predicting incorrect metered-dose inhaler technique in older subjects. *Arch of Intern Med* 1996;156: 984-88.
65. Toso C, Williams DM, Noone P. Inhaled Antibiotics in Cystic Fibrosis: A Review. *Ann Pharmacother* 1996;30:840-50.
66. Pleasants RA, Michalets EL, Williams DM, Samuelson WM, Rehm JR, Knowles MR. Pharmacokinetics of Vancomycin in Adult Cystic Fibrosis Patients. *Antimicrob Agents Chemo* 1996; 40 (1):186-90.

67. Gray SL, Nance AC, Williams DM, Pulliam CC. Assessment of Interrater and Intrarater Reliability in the Evaluation of Metered Dose Inhaler Technique. *Chest* 1994;105:710-714.
68. Kirk JK, Dupuis RE, Miles MV, Gaddy GD, Miranda-Massari JR, Williams DM. Salivary Theophylline Monitoring: Reassessment and Clinical Considerations. *Ther Drug Monit* 1994;16(1):58-66.
69. Williams DM. Pharmaceutical Care for Patients with Asthma. Proceedings of the Section of Community Pharmacists. World Congress of Pharmacy & Pharmaceutical Sciences. International Pharmacy Federation. Tokyo, Japan. September 9-10, 1993, p. 35-38.
70. Pleasants RA, Vaughan LM, Williams DM, Fox JC. Compatibility of Ceftazidime and Aminophylline Admixtures for Different Methods of Intravenous Infusion. *Ann Pharmacother* 1992;26:1221-6.
71. Page JC, Abramson C, Lee WL, McCarthy DJ, McGinley KJ, Williams DM. Diagnosis and Management of Tinea Pedis. *J Amer Pod Med Assoc* 1991;81(6):304-16.
72. Williams DM. Phenylpropranolamine Hydrochloride. *Am Pharm* 1990;NS 30(10):47-50.
73. Pleasants RA, Williams DM, Waltner WE, Knowles MR. Influence of Infusion Method on Serum Tobramycin Concentrations in Adults with Cystic Fibrosis. *Clin Pharm* 1990;9:541-5.
74. Williams DM. Basic Bibliographies: Chronic Obstructive Pulmonary Diseases. *Hosp Pharm* 1994.
75. Pleasants RA, Williams DM, Fus AS, Leathers CM, Waltner WE. Tobramycin Administration and Blood Sampling Through a Dual-Lumen Peripheral Catheter. *DICP* 1989;23:460-3 .
76. Pleasants RA, Williams DM, Porter RS, Gadsden RH. Reassessment of Cross-Reactivity of Spironolactone Metabolites With Four Digoxin Immunoassays. *Ther Drug Monit* 1989;11(2):200-4.
77. Williams DM, Cubeddu LX. Amlodipine Pharmacokinetics in Healthy Volunteers. *J Clin Pharmacol* 1988;28:990-4.
78. Pleasants RA, Sawyer WT, Williams DM, et al. Accuracy of Tobramycin Delivery by Four Intravenous Methods. *Clin Pharm* 1988;7:367-73.
79. Pleasants RA, Sawyer WT, Williams DM, et al. Effect of Four Intravenous Infusion Methods on Tobramycin Pharmacokinetics. *Clin Pharm* 1988;7:374-9.
80. Williams DM. "Ask Your Pharmacist" Consumer Phone-in Program in North Carolina. *Am J Hosp Pharm* 1987;44:1631-2.
81. Williams DM, Daugherty LM, Aycock DG, Lindley CM, Harris MJ. Effectiveness of Improved Targeting Efforts for Influenza Immunization in an Ambulatory Care Setting. *Hospital Pharmacy* 1987;22(5):462-4.
82. Lindley CM, Mackowiak JI, Williams DM, Hak SH. Ambulatory Care Pharmacy Practice Course: Introduction and Evaluation of Oral Examinations. *Am. J. Pharm. Ed.* 1986;50:268-74.
83. Sawyer WT, Poe TE, Canaday BR, Weiner JS, Williams DM, Webb CE, Ellison MJ. Multicenter Evaluation of Six Methods for Predicting Warfarin Maintenance Dose Requirements from Initial Response. *Clin Pharm* 1985; 4:440-6.

## ***Nonreferred Articles***

1. Type II Inflammation in Asthma. (Monograph). Postgraduate Health Education 2019.
2. Williams DM. COPD: Improving Disease Management. Pharmacy Times 2015 (March 23): Published Online.
3. Williams DM. Introduction to Pulmonary Medicine (II). J Pharm Pract 2001;14(3): 164-5.
4. Ciminelli AM, Dupuis R, Williams DM, Hollar K, Fair JH, Johnson M, Gerber D. Patient education role of a pharmacist on a transplant service. Am J Health-Syst Pharm 2000;57(15):767-8.
5. Williams DM. Basic Bibliographies. Chronic Obstructive Pulmonary Disease. Hosp Pharm 2000;35(11):1252-4.
6. Sutton LB, Williams DM. The One-Minute Counselor: A Pharmacist's Guide to Tuberculosis. J Amer Pharm Assoc 1996;NS36(3): 153-4.
7. Williams DM. The One-Minute Counselor: A Pharmacist's Guide to Infectious Complications in AIDS Patients. J Amer Pharm Assoc 1996;NS36.
8. Sutton LB, Williams DM. Management of COPD. NARD Journal 1995; 7: 53-7.
9. Williams DM. The One-Minute Counselor: A Pharmacist's Guide to Sexually Transmitted Diseases. Am Pharm 1995;NS35(8):
10. Williams DM. Asthma management can save lives. Am Pharm. 1995; NS35(11): 3.
11. Williams DM. Basic Bibliographies: Chronic Obstructive Airways Disease. Hosp Pharm 1994; 29(5): 515-8.
12. Williams DM. The One-Minute Counselor: The Pharmacist's Guide to Managing Chronic Obstructive Pulmonary Disease. Am Pharm 1993; NS33.
13. Williams DM. The One-Minute Counselor: A Pharmacist's Guide to Inhalation Therapy for Asthma. Am Pharm 1992;NS32
14. Williams DM. Beta-agonist therapy: MDI or nebulizer. Am Pharm 1991;NS31(9):644-646.
15. Williams DM. The pharmacology of beta agonists in asthma therapy. NARD Journal 1990;112(5):59-61.
16. Williams DM. Hepatitis B Vaccine: how beneficial? U.S. Pharm 1985; 10(11):54-6.
17. Williams DM. Pharmacy and the hypertensive patient. The Kentucky Pharmacist 1978; 41(6):22.

## **Letters**

1. Brock TP, Williams DM. Community Pharmacists as medication educators. J Allergy Clin Immunol 2002;110: 201.
2. Williams DM. How far we have come, or not. Pharmacy Today 1996; 2(4): 16.

3. Williams DM, Figg WD, Pleasants RA. Ranitidine does not inhibit theophylline metabolism. (Letter) DICP, The Annals of Pharmacotherapy 1991;24:1140.
4. Williams DM. Asthma in children. (Letter) Clinical Pharmacy 1992;11:386-387.
5. Williams DM. Loperamide in children. (Letter) American Pharmacy 1991;NS31(9):614.
6. Williams DM. Pneumococcal Vaccine (Letter). Hosp Pharm 1991;26:270-71.
7. Williams DM. Pharmacotherapeutics Texts (Letter). Am J Pharm Ed 1990;54:483.
8. Pleasants RA, Williams DM. Simple Conversion from Intravenous Aminophylline to Twice Daily Oral Theophylline (letter). Chest 1989;96(6):1440.
9. Williams DM, Pleasants RA. Comment: Metered-Dose Inhalers (letter). DICP 1989;23:815-6.
10. Williams DM. Prednisone versus Prednisolone, a Clarification (letter). The Kentucky Pharmacist 1982; 45(12):391.

### ***Monographs***

1. Disease Management Algorithms., APhA, 1996 (Primary Author: COPD); Review Panel (Acute Asthma; Allergic Rhinitis)
2. Kuhn RJ, Samuelson W, Williams DM. Pharmacologic Management of Airway Secretions in Cystic Fibrosis. Univ of Ky ACPE #022-000-95-040-H01. 1995.
3. Pittman AW, Williams DM, Patterson JH. Hypertension: Trends in Pharmacotherapy. Health Sciences Consortium. Chapel Hill, NC 1990.
4. Williams DM. Athlete's Foot: Evolving Concepts in the Diagnosis and Treatment of Pedal Infections. McCarthy Medical Marketing. New Rochelle, NY 1990.
5. Williams DM. Inhalation Therapy for Pulmonary Diseases (Parts 3, 4, 5). Health Sciences Consortium, Chapel Hill, North Carolina 1989.
6. Pittman AW, Williams DM, Patterson JH. Hypertension: Current and Future Trends. Health Sciences Consortium. Chapel Hill, North Carolina 1987.
7. Williams DM. Antimicrobial Prophylaxis (3 monographs). Health Sciences Consortium. Carrboro, North Carolina 1985.

### ***Other Articles***

1. Williams DM. COPD: Improving Disease Management. Pharmacy Times 2015 (March 23): Published Online.
2. Williams DM. The Pharmacist's Role in the Treatment of Asthma: One Minute Counselor. JAPhA 1998;38(1):107-8.
3. Williams DM. Therapeutic Management of Asthma and COPD. Primary Care 1997;1(1): 45-7.
4. Tuberculosis Skin Testing and Decision-Making. NCSHP Newsletter 1991 (Aug);14(4):4.
5. Williams DM. The 'Compleat Pharmacist.' APPM Update 1991;26(2):2-3.

6. Williams DM. The Entry-Level Pharm.D. Degree: Impact on the B.S. Practitioner. *APPM Update* 1990;25(3):1-2.

### ***Other Publications***

1. Chair, Editorial Advisory Board. APhA Report. Asthma; The Role of the Pharmacist....
2. Editorial Advisory Board. APhA New Product Bulletin. Aldara. May 1997

### ***Other Audio Video Educational Materials***

1. The Role of the Pharmacist in Improving Asthma Care: Interactive CD-Rom. American Pharmaceutical Association. 1999
2. Asthma Update: Audiotape CE. Clinical Communications. 1996
3. The Role of the Pharmacist in Asthma Care: Videotape CE. Annenberg Center, Palm Desert CA, 1994.
4. Medical Outlook: Chronic Obstructive Pulmonary Diseases: Audiotape CE. American Society of Consultant Pharmacists. 1994.

### ***Abstracts/Poster Presentations***

1. Kufel WD, Daniels LM, Marx AH, Williams DM. Antimicrobial stewardship education among US colleges and school of pharmacy. American College of Clinical Pharmacy Annual Meeting, Phoenix, AZ, August 2017 [poster presentation].
2. Corbett A and Williams D. Introduction of an integrative medicine elective at the UNC Eshelman School of Pharmacy. American Association of Colleges of Pharmacy Annual Meeting. July 2011 [Poster presentation].
3. Patel-House S, Williams DM, Barrow J. Impact of initiation of antibiotic therapy on INR results in patients treated with warfarin. Acute Care Practice Forum, NCAP. Winston-Salem, NC. March 26, 2011
4. Webb A, Williams DM, Barrow J. Efficiency of vancomycin dosing strategies in adult patients with cystic fibrosis. North Carolina Pharmacists Association Meeting. Concord, NC. March 2010.
5. Abramson S, Arney TD, Bell C, et al. National Asthma Educator Certification: Purpose, progress and promise. Annual Meeting. American College of Asthma, Allergy, and Immunology. New Orleans, LA. February 27, 2010.
6. Abramson S, Arney TD, Bell C, et al. National Asthma Educator Certification: Purpose, progress and promise. American Academy of Nurse Practitioners National Conference. Phoenix, Arizona. June 24, 2010.
7. Mehrizi A, Barrow J, Williams DM. Characterization of Tobramycin Pharmacokinetics in Cystic Fibrosis Patients. Poster Presentation. NCAP Acute Care Practice Forum Spring Meeting, Concord, NC. March 2009
8. Williams DM. Rapid and enduring relief of nasal congestion: Assessment of data on mometasone furoate nasal spray regarding onset of action and duration of efficacy. Poster Presentation, Midyear Clinical Meeting, ASHP. Orlando Florida December 2008

9. Rivera R, Campbell-Bright S, Bourdet SV, Williams, DM. A concurrent analysis of antimicrobial use in medical intensive care patients developing pulmonary infiltrates greater than 48 hours after hospitalization. ASHP Midyear Clinical Meeting. New Orleans, LA. December 2003.
10. Smyth HDC, Meija-Millan, EA, Williams DM, Zeman KL, Bennett WD, Hickey AJ. The effect of formulation variables on lung deposition: Labeling of pMDI solutions. AAPS Annual Meeting, Toronto, Canada, November 2002.
11. Mando J, Campbell-Bright S, Bourdet SV, Williams, DM. Evaluation of a insulin infusion protocol for patients in medical intensive care. ASHP Midyear Clinical Meeting. Las Vegas, NV. December 2002.
12. Brock TB, Wessell A, Williams DM. Float Characteristics of Commercially Available Metered Dose Inhaler products. American Pharmaceutical Association Annual Meeting March 2001; Los Angeles, CA. (APhA-APPM Presentation Merit Award)
13. Williams DM, Wessel A, Williams M, Brock TB. Albuterol dose response curves when administered through aerochamber compared to easivent. ACCP Fall Meeting 2001. Tampa, Florida. October 2001.
14. Bourdet SV, Williams DM. Comparison of simultaneous serum concentration sampling of aminoglycosides for central catheters and peripheral venous sites. ASHP Midyear Clinical Meeting 2001, New Orleans, LA. December 2001.
15. Belanger JA, Williams DM. Evaluation of vancomycin serum concentration sampling strategies in a tertiary care center. ASHP Midyear Clinical Meeting 1999.
16. Freeman-Newsom JK, Brock TP, Williams DM. Evaluation of Smoking Cessation Activities by Community Pharmacists. APhA Annual Meeting. Miami Beach, Florida. March 22, 1998.
17. Williams DM. Considerations in the Medical Management of the Adult Cystic Fibrosis Patient. Int Pharm Abst 1998; 35(9): 3505349.
18. Freeman-Newsom JK, Brock TP and Williams DM. "Evaluation of Smoking Cessation Activities by Community Pharmacists," presented at the 145th Annual Meeting of the American Pharmaceutical Association in Miami, FL. March 1998 (APhA-APPM Presentation Merit Award)
19. Deaton AT, Dunbar CA, Williams DM, Hickey AJ. Production of spray dried semisolid particles containing budesonide. PharmSci. American Association of Pharmaceutical Scientists 1998; 1(1) :s214 (2269)
20. Deaton AT, Dunbar C, Williams DM, Hickey A. Generation of novel gel aerosols by commercially available nebulizers. Undergraduate Research Seminar, Morgantown, West Virginia. October 1997.
21. Hollar K, Dupuis RE, Williams DM, Dennis BH, Joy M. Corticosteroid-Induced Osteoporosis: Assessment of Risk and Prescribed Therapy in Organ Transplant Recipients and Patients with Pulmonary Disease. Int Pharm Abst 1997; 34.
22. Williams DM. Pharmacologic Treatment of Chronic Asthma. Int Pharm Abst 1997; 34:PI-3.
23. Kirk JK, Dupuis RE, Miles MV, Miranda JR, Williams DM. Relationship between saliva and serum theophylline concentrations: A comparison of two assays and two saliva stimulation methods. ACCP Abstract.
24. Nagle BL, Williams DM, Pulliam CC, Donahue JF. Effect of metered-dose inhaler technique on quality of life in patients with obstructive airways disease. American College of Clinical Pharmacy, Winter Meeting, Ft. Lauderdale, FL, February 16, 1993

25. Kozlowski MA, Williams DM. Foscarnet-Induced Genital Ulcerations. ASHP 28th Midyear Clinical Meeting, Atlanta, GA. December 9, 1993.
26. Gray SL, Williams DM, Pulliam CC, et al. "Predictors of Correct Metered Dose Inhaler Technique in Older Individuals," American Thoracic Society Annual Meeting, Miami, FL, May 19, 1992.
27. Gray SL, Williams DM, Pulliam CC, Donahue JF, Bishop AL, Sirgo MA. Predictors of correct metered-dose inhaler technique in older individuals. First National Conference on Asthma Management, Arlington, VA, October 12, 1992.
28. Gray SL, Nance AC, Williams DM, Pulliam CC. Assessment of inter and intra-rater reliability of metered-dose inhaler technique. First National Conference on Asthma Management, Arlington, VA, October 12, 1992.
29. Kirk JK, Dupuis RE, Miles MV, Miranda JM, Williams DM. Comparison of a dry reagent method with fluorescence polarization immunoassay for the determination of salivary theophylline concentrations. *Pharmacother* 1992;12(3):248.
30. Gray SL, Williams DM, Pulliam CC, et al. Predictors of correct metered-dose inhaler technique in older individuals. *Am Rev Resp Dis* 1992;145(4):A500
31. Gray SL, Williams DM, Bishop A, Pulliam C. "Impact of Education Program on Older Patient's Use of Metered Dose Inhalers." American Society of Consultant Pharmacists Annual Meeting, Montreal, Canada, October 1991.
32. Pleasants RA, Vaughan LM, Williams DM. Compatibility of ceftazidime and aminophylline admixtures used for constant infusion. American College of Clinical Pharmacy Annual Meeting, Minneapolis, MN, August 1991 and *Pharmacother* 1991;11(3):276.
33. Pleasants RA, Williams DM, Waltner WE, Wager G, Knowles MR. Comparative Disposition of Tobramycin in Adult Cystic Fibrosis Patients and Normal Adults. North Carolina Society of Hospital Pharmacists, Winter Meeting, February 1989 and *Clin Pharmacol Ther* 1989;45(2):150(PIII-5) and American College of Clinical Pharmacy, San Francisco, CA, August 8, 1990. *Pharmacotherapy* 1990;10(3):234.
34. Williams DM, Pleasants RA, Fus A, Blum RA, Waltner WE, Knowles MR. Influence of Peak Sampling Time on Prediction of Aminoglycoside Serum Concentrations. American Society of Hospital Pharmacists, 23rd Annual Midyear Clinical Meeting, Dallas, Texas. December 7, 1988 and *Inter Pharm Abst* 1989;26:543 and North Carolina Society of Hospital Pharmacists, Winter Meeting, February 1990.
35. Daugherty LM, Aycock DG, Williams DM, et. al. Single Dose Treatment of Urinary Tract Infections with Co-trimoxazole in an Ambulatory Care Patient Setting. American Society of Hospital Pharmacists, 21st Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 1986 and North Carolina Society of Hospital Pharmacists, Winter Meeting, February 1987.
36. Williams DM. "Ask Your Pharmacist" Phone-In Event-The Second Year's Experience. American Society of Hospital Pharmacists, 21st Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 1986 and North Carolina Society of Hospital Pharmacists, Winter Meeting, February 1987.
37. Williams DM, Pleasants RA, Gadsden RH, Porter RS. Evaluation of Cross-Reactivity of Spironolactone Metabolites with Four Digoxin Immunoassays. American Society of Hospital Pharmacists, 22nd Annual Midyear Clinical Meeting, Atlanta, Georgia. December 1987.

38. Pleasants RA, Williams DM, et al. Influence of Intravenous Infusion Methods on Tobramycin Serum Concentration and Pharmacokinetics in Adult Cystic Fibrosis Patients. *Pediatric Pulmonary* 1987;3(Suppl 1):128 and 1987 Cystic Fibrosis Conference, Toronto, Canada October 1987 and North Carolina Society of Hospital Pharmacists, Winter Meeting, February 1988 and American College of Clinical Pharmacy, Kansas City, Missouri, August 1989. *Pharmacotherapy* 1989;9(3):186.
39. Dupuis R, Pleasants R, Williams D, et al. Use of a Bayesian Program to Predict Serum Theophylline Concentrations in Adult ICU Patients. *American Society of Hospital Pharmacists, 21st Annual Midyear Clinical Meeting, Las Vegas, Nevada. December 1986.*
40. Pleasants RA, Powell JR, Williams DM, et. al. Effect of Four Intravenous Infusion Methods on Tobramycin Serum Concentration Data in Normal Volunteers. *American Society of Hospital Pharmacists, 21st Annual Midyear Clinical Meeting, Las Vegas, Nevada. December 1986.*
41. Williams DM, Rice TL. Interest in a Pharmacokinetic Consultation Service in an Ambulatory Care Practice. *American Society of Hospital Pharmacists, 20th Annual Midyear Clinical Meeting. New Orleans, Louisiana. December 1985.*
42. Mackowiak JI, Lindley CM, Williams DM. Evaluating Clinical Education in Ambulatory Care: Effectiveness of Oral Exams. *Proceedings of the 86th Annual American Association of Colleges of Pharmacy. San Francisco, California. July 1985.*
43. Lindley CM, Williams DM, Aycock DG, Daugherty LM, Caiola SM, Godfrey WS. The Effect of Increased Accessibility to Patient-Specific Information on Pharmacists' Interventions. *American Society of Hospital Pharmacists, 20th Annual Midyear Clinical Meeting. New Orleans, Louisiana. December 1985.*
44. Sawyer WT, Poe TE, Canaday BR, Weiner JS, Williams DM, Webb CE. Prediction of Warfarin Maintenance Dose from Initial Response: Comparison of Six Methods. *American Society of Hospital Pharmacists, 19th Annual Midyear Clinical Meeting. Dallas, Texas. December 1984.*
45. Williams DM, Lindley CM, Daugherty LM, Godfrey WS. Evaluation of an Influenza Immunization Program in an Ambulatory Health Care Institution. *American Society of Hospital Pharmacists, 19th Annual Midyear Clinical Meeting. Dallas, Texas. December 1984.*
46. Lindley CM, Williams DM, Daugherty LM, Garcia LT, Godfrey WS. Substitution of Transderm<sup>R</sup> Nitro for Nitrol<sup>R</sup> Ointment: A Therapeutic Equivalence Evaluation and Cost-Benefit Analysis. *American Society of Hospital Pharmacists, 19th Annual Midyear Clinical Meeting. Dallas, Texas. December 1984.*
47. Lindley C, Almond S, Griffin N, Huff P, Williams D. Use of Atenolol in an Ambulatory Care Population: Cost Versus Benefit. *American Society of Hospital Pharmacists, 18th Annual Clinical Midyear Meeting. Atlanta, Georgia. December 1983.*

### ***Book Reviews***

1. Williams DM. Principles of Drug Action: The Basis of Pharmacology. (Pratt & Taylor). In: *Pharmacy Focus* 1991;4(2):1.
2. Lindley CM, Williams DM. Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Edition. In: *DICP: The Annals of Pharmacotherapy* 1990;24:1238.
3. Williams DM. Clinical Pharmacy and Therapeutics, Fourth Edition. In: *Clin Pharm* 1990;9:226-7.
4. Williams DM. Mechanisms in Asthma: Pharmacology, Physiology and Management. In: *Am J Pharm Educ* 1989;53(1):104.

## ***Teaching Activities***

1. Pharmacy 502: Evidence-based Practice. Lecturer 2015-present
2. Pharmacy 504: Pathophysiology. Lecturer 2015-present
3. Pharmacy 509: Immunization Certificate Training Program. Lecturer 2015-present
4. Pharmacy 510: Foundations in Pharmacology. Lecturer 2016-present
5. Pharmacy 529: Foundations in Pharmacotherapy. Lecturer and Case Developer 2017-present
6. Pharmacy 611: Applied Pharmacology. Lecturer 2016-present
7. Pharmacy 630: Applied Pharmacotherapy Course. Lecturer and Case Developer 2016-present (Co-director 2018)
8. Pharmacy 631: Integrative Pharmacotherapy I. Facilitator and Case Expert 2016-present
9. Pharmacy 732: Integrative Pharmacotherapy II. Facilitator and Case Expert 2017-present
10. Pharmacy 733: Integrative Pharmacotherapy III. Facilitator and Case Expert 2018-present (Co-director 2019)
11. PASC (Physicians Assistant) 711: Pharmacology and Pharmacotherapy I. Course Director 2016, 2017
12. PASC (Physicians Assistant) 721: Pharmacology and Pharmacotherapy II. Course Director 2016, 2017
13. PASC (Physicians Assistant) 731: Pharmacology and Pharmacotherapy III. Course Director 2016, 2017
14. *Pharmacotherapy and Experimental Therapeutics 823: Elective International Clinical Classroom. Course Director since 2011*
15. *Pharmacotherapy and Experimental Therapeutics 811: Infectious Diseases Elective Course Co-Director S2013-2017*
16. *Pharmacotherapy and Experimental Therapeutics 803: Ambulatory Core Therapeutics*
17. *Pharmacy 491 and 492: PY4 Seminar and Case Conference (Assistant Director) (1hour)*
18. *Pharmacy 450: Problems in Pharmacotherapy (5hours)*
19. *Pharmacy 449: Infectious Diseases Therapeutics (3hours)*
20. *Pharmacy 445: Pulmonary and GI Therapeutics (2hours)*
21. *Pharmacy 444: Cardiology/Nephrology (4hours)*
22. *Pharmacy 442: Introduction to Pharmacotherapy (4hours)*
23. *Pharmacy 441: Immunization Certificate Course (1hour)*
24. *Pharmacy 433: Drug Literature Interpretation and Analysis (Co-Director) (4hours)*

25. *Pharmacy 423: Medicinal Chemistry Autonomics (2hours)*
26. *Pharmacy 402: PCL Year 1 (2hours) Medicine 238: Pharmacology (Medicine) (2hours) Nursing 229: Advanced Pharmacotherapy (Nurse Practitioners) Asthma and COPD (3 hours)*
27. *OMSU 220: Pharmacotherapy for Dental Graduate Students Asthma and COPD (2 hours)*
28. *Pharmacy 203: Physiology (4hours) 162 students enrolled*
29. *Pharmacy 169: Problems in Pharmacotherapy. Serve as faculty facilitator for small group discussions of complex cases (6 hours/week)*
30. *Pharmacy 152: Infectious Diseases. Coordinator for 3 hour course; Integration of medicinal chemistry and pharmacotherapy concepts and applications; Present 8 –10 lecture hours*
31. *Pharmacy Practice 110: Ambulatory Care Pharmacy Practice. Led discussion and student presentations on pulmonary topics (3 hours)*
32. *Pharmacy 85: Cardiology and Nephrology Therapeutics. Acid-Base Disorders (2 hours)*
33. *Pharmacy 82: Applied Pharmacokinetics. Theophylline Pharmacokinetics (2 hours)*
34. *Pharmacy 75: Autonomic Nervous System, Pulmonary and Gastrointestinal Therapeutics. Coordinator for 3 hour course; Develop syllabi for pulmonary module; Present 10-12 lecture hours*
35. *Pharmacy 73 & 63: Rheumatology and Endocrinology. Inflammation, Corticosteroids, Osteoarthritis, and Rheumatoid Arthritis (5 hours)*
36. *Clinical Clerkships .Precept 4 to 6 students annually on pulmonary medicine or infectious disease medicine clerkships at UNC Hospitals*
37. *Dental Pharmacology: Eckel (Summer) (2hours) 20 students enrolled*
38. *Immunology. Immunizations and Vaccines: (4 hours)*
39. *Pharmacology: Hadler (Medicine) (2 hours) 44 students enrolled*

### ***Grants and Contracts***

Principal Investigator: Pharmacology and Pharmacotherapy Instruction for Physicians Assistant Program, Allied Health, UNC School of Medicine 2016. \$28,000

Co-Investigator: The Air You Breathe Campaign: A Targeted and Innovative Approach to Promoting Treatment Guidelines and Educating Practitioners. Eshelman Institute for Innovation, Laura Bowers, PI. \$25,000

Co-Investigator: The effect of risk and side effect communication on asthma adherence. AHRQ (PI: Chris Gillette, Ph.D. Candidate) (June 2011- April 2012)

Co-Investigator: Children and Asthma: Communication and outcomes. National Institutes of Health. \$1,425,034. (P.I. Betsy Sleath, Ph.D.) (2005-2009). (Percent Effort 10%)

Co-Investigator: Enhancing Pneumococcal Vaccination Rates through Community Pharmacy Involvement. Centers for Disease Control. \$221,159 (P.I.: Stephanie Ferreri, Pharm.D.) (September 2005-September 2008). (Percent Effort 5%)

From Metered Dose Inhalers Based on Formulation Variables. Source: GSK Clinical Applications Investigator Initiated Awards, \$24,000 (January 2004; Not Funded).

Principal Investigator: Predicting aerosol device performance to enhance therapeutic efficacy. ACCP Career Development Grant Award, \$50,000. (April 2004; Not Funded).

Co-Principal Investigator: The influence of vapor pressure on performance of propellant driven metered dose inhalers. (Anthony Hickey, Co-PI). PhRMA Foundation Award for Undergraduate Research, \$7,500. Student: Elizabeth Mejia-Milan. (completed May 2003).

Principal Investigator. Factors influencing Adherence with Medications in Patients with COPD. Clinical Application Grant \$10,000 (completed December 2003).

Co-Investigator: Use of biologic response modifiers in rheumatoid arthritis: A study of the natural history of therapy (Sue Blalock, PI). Source: Arthritis Foundation, \$552,000 (July 2003; Not Funded).

Principal Investigator: Efficient Inhaler Performance for Asthma Therapy: Prediction of Lung Deposition

Principal Investigator: Compliance-Efficacy Interactions, C-E Ratios, and Asthma. Astra Clinical Pharmacy Research Grant Award. \$10,000.00. (12/97- 6/99)

Principal Investigator: A Pharmacist-Managed Asthma Intervention Program. University Research Council Grant \$1500.00 (5.97-4/99).

Co-Principal Investigator: A Randomized, Double-blind, Placebo-Controlled, Comparative Trial of Fluticasone Propionate 440mcg BID or 880 mcg BID Versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid-Dependent Asthmatics. Protocol FLTA3022. Glaxo Wellcome Inc. (12/97- 2/98) \$54,000.00.

Principal Investigator: Generation of Novel Gel Aerosols by Commercially Available Nebulizers. UNC School of Pharmacy Faculty Seed Grant. (11/1/96-10/31/97). \$1800.00

Principal Investigator: Evaluation of Pharmacist Involvement in and Expectations from Smoking Cessation Interventions. UNC Junior Faculty Development Award. (1/1/97-12/31/97). \$5000.00

Co-Investigator. A Double-Blind, Placebo-Controlled Safety Trial of Nebulized Amiloride Hydrochloride in Pediatric Patients with Cystic Fibrosis.(AML-310:IND #. 18,382) ( P.I. Robert Wood, M.D., Ph.D.) 1996 Glaxo, Inc. \$50,000.

Principal Investigator: Integrating Student Society Chapters into the Operational Infrastructure of an Established State Society. American Society of Health-System Pharmacists Affiliated State Chapter Projects Grants Program. 1996. \$500.00

Principal Investigator: Consultant for Pharmacy Operations: Contractual Services. Orange Country Health Department. \$5,000. (Annual; 1987-1995).

Comprehensive Asthma Management Program in Elementary Schools. Submitted in response to RFP (NIH Contract) January 1995: \$7,000,000 over 5 years. (unfunded) P.I. Fred Henderson, M.D.

Multicenter Approach Impact of Provider-Patient Drug Education Intervention. Submitted to AHCPR 1995 (April) (1 R01 HS 09081 01) \$6.4 million over 5 years (Unfunded) P.I. Joe Norwood, Ph.D.

Comparison of PEFR Monitoring versus Symptom Diaries for Elderly Patients with Asthma. Submitted to School of Pharmacy Seed Grant Committee 1994 (unfunded)

Principal Investigator: An Evaluation and Comparison of Isradipine versus Hydrochlorothiazide in the Regression of Left Ventricular Hypertrophy Secondary to Hypertension. Glaxo Inc. \$100,320.00 (Completed 7/92).

Co-Principal Investigator: A Multicenter Comparison of the Safety and Efficacy of Lomefloxacin and Cefaclor in the Treatment of Acute Exacerbations of Chronic Bronchitis. G.D. Searle & Co. \$15,000 (Co-P.I.: James Donohue, M.D.) (Completed 06/90).

Co-Principal Investigator: Modern Approach to the Treatment of Hypertension. Pfizer Laboratories Division. \$15,000. (Co-P.I.: Luigi Cubeddu) (Completed 1/90).

Principal Investigator: Evaluation of the Efficacy of Pseudoephedrine in the Prevention of Symptoms of Middle Ear Barotrauma Associated With Air Travel. Burroughs Wellcome Co. \$14,000.00 (Completed 11/90).

Co-Principal Investigator: An Evaluation of Bioavailability of Rifampin Suspension and Capsules in Normal Male Volunteers. Carolina Medical Products \$26,450. (Co-P.I.: Roy Pleasants, Pharm.D.) (Completed 2/88).

Co-Investigator: Evaluation of a Dual-Lumen Catheter for Tobramycin Serum Concentration Determination. Arrow International, Inc. \$7,695. (P.I.: Roy Pleasants, Pharm.D.) (Completed 2/88)

Co-Investigator: Evaluation of Pharmacokinetics and Pharmacodynamics of Single Doses of Anipamil Hydrochloride in Patients with Mild to Moderate Hypertension. Knoll Pharmaceuticals \$56,000 (PI: Luigi Cubeddu, M.D., Ph.D.) (Completed 8/87).

Co-Investigator: Effect of IV Infusion Method on Tobramycin Serum Concentration Data in Adult Cystic Fibrosis Patients. Becton-Dickinson \$5,000 (P.I.: Roy Pleasants, Pharm.D.) (Completed 7/87).

Co-Principal Investigator: Evaluation of Bioavailability of Spironolactone Suspension in Normal Male Volunteers. Carolina Medical Products \$25,280 (Co-P.I.: Roy Pleasants, Pharm.D.) (Completed 6/87).

Co-Investigator: Effect of Step-Down Diuretic Therapy on Blood Pressure Control & Biochemical Parameters in Patients with Essential Hypertension. Unfunded (With: Celeste Lindley, Pharm.D.) (Completed 3/87).

Co-Investigator: Effect of Food on Doxazosin Bioavailability in Normal Volunteers. Pfizer, Inc. \$35,700 (PI: Luigi Cubeddu, M.D., Ph.D.) (Completed 1/87).

Co-Investigator: Pharmacokinetics of Amlodipine in Healthy Volunteers. Pfizer, Inc. \$24,680 (PI: Luigi Cubeddu, M.D., Ph.D.) (Completed 7/86).

Co-Investigator: Effect of Four Intravenous Infusion Methods on Tobramycin Serum Concentration Data in Normal Volunteers. Becton Dickinson, Abbott, Lilly, Various \$10,000. (P.I.: Roy Pleasants, Pharm.D.) (Completed 12/86).

Co-Investigator: The Effect of Increased Accessibility to Patient Specific Information on Pharmacists' Intervention Activities. Pharmacy Foundation of North Carolina \$1,500. (P.I.: Steve Caiola, M.S.) (Completed 12/85).

Co-Investigator: Use of a Bayesian Program to Predict Serum Theophylline Concentrations. Abbott Laboratories, Therapeutic Software Division \$2,500 (P.I.: Bob Dupuis, Pharm.D.)

Principal Investigator: Drug Abuse Education Project, Academy of Students of Pharmacy. Submitted to: Greater Triangle Community Foundation \$12,000.00 (unfunded)

Co-Investigator: Compatibility and Stability of Admixtures of Intravenous Ceftazidime and Aminophylline. Glaxo Inc. \$17,748.00 (P.I.: Roy Pleasants, Pharm.D.)

Sub-Investigator: Mental Status and Hand Strength as Predictors of Correct Metered Dose Inhaler Technique. Glaxo Inc. \$18,612.00 (P.I.: Becky Nagle, Pharm.D. Fellow)

Principal Investigator: Evaluation of the Efficacy of Pseudoephedrine in the Prevention of Symptoms of Middle Ear Barotrauma Associated With Air Travel (II). Burroughs Wellcome Co. \$114,000.00

Impact of MDI Technique on Elderly Patients' Quality of Life (Principal Investigator: Becky Nagle, Pharm.D.) Glaxo Research Institute, \$50,000.

Principal Investigator: A Randomized, Three-Way, Comparative Trial of Albuterol Metered-Dose Inhaler (MDI), Albuterol MDI with an Aerochamber Valved Holding Chamber, and Albuterol MDI with an EasiVent Valved Holding Chamber. Dey Laboratories LP. \$16,560.

Principal Investigator: Aerosol Delivery of Corticosteroids as Asthma Therapy. National Heart, Lung, and Blood Institute Career Development Award Grant (NIH K08). \$604,897 (not funded).

### ***Professional Service Organizations***

Board of Pharmaceutical Specialties Council: Infectious Diseases Pharmacotherapy 2017- 2019

Allergy and Asthma Network, Vienna, Virginia, Board of Directors 2015- 2020

Executive Committee 2017-2020

Education Committee 2017-2020

Carolinas-Honduras Health Foundation, Board of Directors 2016-2020

Opioid Risk Reduction Task Force, Orange County Health Department 2016-2017

COPD Foundation, Washington, DC, Member, Research Committee 2015-2018

Advisory Panel, Immunizations Mentor Program, American Society of Health System Pharmacists 2013

*United States Pharmacopeia Convention*

Delegate representing UNC School of Pharmacy 2011-2020

*National Asthma Educator Certification Board*

Board of Directors 2006-2011

Chair and Executive Committee 2009-2011

National Examination Committee Member 2006-Current

*National Asthma Education and Prevention Program Coordinating Committee (NHLBI)*

Member Representative 1992-2015

### ***Professional Membership Organizations***

*American Society of Health-System Pharmacists*

Faculty Liaison for Students (1992- 2014)

House of Delegates, 1995-2015  
ASHP Research and Education Foundation Fundraising Committee (2006-8)  
Section of Clinical Specialists and Scientists  
Nominations Committee (1996-97, 2003, 2004)  
Chair, Section of Clinical Specialists (1999-2001) (Chair-elect, Chair, Past Chair)  
Committee on Nominations 1999  
Continuing Education Committee, Section of Clinical Specialists (1997-1998)  
Chair 1998  
Council on Professional Affairs 1997, 1998  
Vice-Chair 1998  
Membership Recruitment and Retention Advisory Committee (1996- 1998)

*American Pharmacists Association*

Policy Committee 2018  
House of Delegates 2018, 2019  
Joint Council of Allergists and Pharmacists 2002-2012  
APPM Standing Committee on Policy 1994  
APhA Policy Advisory Committee 1994  
Chairman, Section on Clinical/Pharmacotherapeutic Practice, APPM 1993-1994  
APPM Standing Committee on Policy - 1991, 1994  
APhA Policy Advisory Committee - 1991, 1994  
APPM Standing Committee on Education 1993  
APhA Education Advisory Committee 1993  
Member-at-Large, Section on Clinical/Pharmacotherapeutic Practice,  
Academy of Pharmacy Practice & Management - 1990-1991  
Professional Affairs Policy Committee - 1988-1989

*North Carolina Association of Pharmacists (Formerly, North Carolina Society of Hospital Pharmacists)*

Opioid Risk Reduction Education Committee 2018-2019  
Member, Legal and Public Affairs Committee (2001-Current)  
Editorial Board, Journal (2003-2012)  
Treasurer (2010-2015)  
Board Member (2007-2015)  
Executive Director Search Committee (2013-2015)  
Presidential Officer (2007-2009)  
Board of Directors 1992-1997, 1998-2000, 2007-2015

*North Carolina Pharmaceutical Association*

Chair, Committee on Resolutions 1997  
Presidential Officer (1995-1997)  
Ex-Officio member of Board of Directors 1996  
Communications and Public Relations Committee 1989-1990, 1994  
Membership Committee 1983, 1984 (Chairman) 1988-1990, 1994  
Public Health Committee 1988-1989, 1991-1993  
Pharmacotherapy Special Interest Group  
(Advisory Committee 1983, 1985-1993) (Chairman, 1991)  
Editorial Advisory Board 1992  
Pharmacy Practice Committee 1989-1992  
Elections Committee Chairman (1990)  
Professional and Public Relations Committee 1985-1990  
Program Committee 1986 (Chairman), 1987 (Chairman) 1988-1990  
Special Committee on Pharmacy as a Clinical Profession 1988-1989  
Coordinator, Annual Poster Session 1987, 1988  
Immunization Advocacy Committee 2015-Present

*American Association of Colleges of Pharmacy*  
Task Force on Women in Academia 1994

*American College of Clinical Pharmacy*  
Education Program Committee for 2013 (2011-13)  
Grant and Fellowship Award Review Committee 2003  
Task Force on Reimbursement for Cognitive Services 1990

*Triangle College of Clinical Pharmacy*

Durham-Orange Pharmaceutical Association  
President 1987-1989  
Executive Committee 1985-1986

Kappa Psi Pharmaceutical Fraternity

Rho Chi Honor Society

Phi Lambda Sigma Pharmacy Leadership Society

Omicron Delta Kappa National Leadership Honorary

***Service: University of North Carolina at Chapel Hill***

Aubrey Brooks Foundation Scholarship Central Selection Committee (2011- 2020)

Health Science Library Advisory Committee (2016-2019)

Scholarship and Financial Aid Committee –General Campus (2009-2013)

***Service: Eshelman School of Pharmacy***

Curriculum and Assessment Committee, Chair 2019-2020

Curricular Implementation and Assessment Committee, Chair 2018-2019

Pharmacotherapy Course Stream Committee 2018-2019

Nominations and Awards Committee 2017-2020

ACPE Self Study Steering Committee, Chair, Standards 2-4 2018-2020

Curricular Innovation and Assessment Committee (2017-2018)

Curricular Transformation Steering Committee (2016-2017)

Global Engagement Advisory Committee (2016-2020)

Rural Health Pharmacy Initiative 2011-2014

Faculty Advisor: Student Pharmacist Opioid Misuse Prevention Task Force (STOMP) (2017-2020)

Faculty Advisor: Interfaith Council Homeless Shelter Clinic (2005- 2016)

Carolina Association of Pharmacy Students (CAPS) Co-Advisor 1996-2014

UNC-CSP Research/Service Project Director 2010-2013

Clinical Working Group-Eshelman School of Pharmacy and UNC Healthcare (2008-2009)

Curriculum Committee Member 2006-2012 (Chair 2010-12)

### ***Service: UNC Hospitals***

#### **Partnership in Patient Care 2.0 Practice Model Change Committee 2018-2020**

Student Resident Advisory Committee (SRAC) 2010-2014

Steering Committee Member 2010-2015

#### **Education Committee 2010-2020**

Pharmacy Operations Council Member 2010-2012

Partnership in Patient Care Initiative

### ***Consultantships***

Immunex Pharmacy Advisory Board 2000

Dey Laboratories Pharmacy Advisory Committee 1998- Current

Health Sciences Consortium 1988 - Current

Orange County Health Department 1987-Current

Advisory Committee for PEAK Study (AHCPR funded) 1993-96

Knott County Health Care Center 1978-1980

Editorial Board: Quality Pharmacy Indicator

Editorial Board: Allergies and Asthma Health: Official Magazine of Allergy and Asthma Network, Mothers of Asthmatics

Expert Testimony presented to U.S. Senate Committee on FDA Proposal for CFC-Phaseout

### ***Faculty Advisor***

#### **A. Undergraduate Honors Program: Research**

1. Anna Cosnahan, Class of 2016: Characterization and Assessment of Azole Antifungal use In Pediatric Patients at UNC Medical Center
2. Dana Kiser (1989 graduate): The role of the Pharmacist in a Multidisciplinary Diabetes Camp: a Demonstration Project.

3. Kevin Layne (1989 graduate): Performance of Various Compressor Nebulizer Systems in the Delivery of Beta Agonists.
4. Terri Howard (1993 graduate): Predictive Performance of Pharmacokinetic Software in Prediction of Theophylline Concentrations.
5. Shelley Adkins (1996 graduate): Impact of NIH Guidelines for asthma Management on therapy.
6. Andrea Wessell: Comparison of FEV1 Response to albuterol inhaled via metered dose inhaler through Aerochamber vs. Easivent

B. Undergraduate Grant Award

Academy of Students of Pharmacy: Merck Company Foundation Student Pharmacy Project Grant 1990: Puppets in the Prevention of Drug Abuse (\$2,000.00).

C. Graduate Student Advisory Committee (SAC)

Nicole Zane (PhD 2016)

D. Dissertation Advisory Committee (DAC)

Erin Burgunder 2018-present

***International Activities:***

Medical Mission Trips to Limon, Honduras as Director of Pharmacy (2017-present)

Faculty Host Delegation from Hiroshima International University School of Pharmacy  
Annual experience to observe/learn about pharmacy education and practice (2011-2020)

Visiting Scholars: Pharmabridge Program:

Clara Adesola (Nigeria 2019)

Lydia Modupe (Nigeria 2016), Uju Anyaebosi (Nigeria 2016)

Kefe Odukuye (Nigeria 2018)

Yasmin El-Sobky (Egypt 2018)

***Service to University***

Interprofessional Education Committee (Health Affairs) 2010-12

Faculty Council 2012-2015

***Other Professional Activities***

Editorial Advisory Board. Asthma and Allergies. Publication of Allergy and Asthma Network/Mothers of Asthmatics 2003-Current.

Editorial Advisory Board, Carolina Pharmacy, Journal of the North Carolina Association of Pharmacists, 2003-2014.

Joint Committee of American Pharmacists Association and American College of Asthma Allergy, Asthma, and Immunology 2002-2010

Editorial Advisory Board. Quality Indicator, Pharmacy Resource. Premier Healthcare Resource, Inc. Parsippany, NJ. 2002-2012

Faculty Coordinator, Interfaith Council Homeless Shelter Medical Clinical (Pharmacy) 2002- 2015

Editorial Advisory Board. Journal of Pharmacy Practice. Sage Publications 2001-Current.

Editorial Advisory Board. Asthma and Allergies. Publication of Allergy and Asthma Network/Mothers of Asthmatics. 2000-Current.

National Asthma Education Program Coordinating Committee (APhA Representative) 1992-2015.

American College of Clinical Pharmacy Grant Selection Committee 2003.

Editorial Advisory Board. APhA Drug Info Line. American Pharmaceutical Association. 2001-2003.

Astra Zeneca Grant Award Review Committee 2000

Editorial Advisory Board, Journal of the American Pharmaceutical Association (formerly American Pharmacy), 1994-1999

American College of Clinical Pharmacy Research Foundation Review Panel (Pulmonary), 1996

### ***Reviewer***

Pediatric Allergy and Immunology

American Journal of Managed Care

American Journal of Health-System Pharmacy

Journal of the American Pharmaceutical Association

Journal of Pharmacy Practice

DICP: The Annals of Pharmacotherapy

Pharmacotherapy

Lippincott's Hospital Pharmacy

The Medical Letter

Posters: ASHP Midyear Clinical and Annual Meetings

USP-DI Monographs

ASCP Research and Education Foundation Peer Review Panel 1992

University of North Carolina Faculty Council Representative 1996-1999; reelected 1999-2001

School of Pharmacy Representative to State Employee Wellness Committee 1989-90

Editor, Non-Prescription Drug Review Series, American Pharmacy 1990-1997

USP Advisory Committee on Clinical Immunology, Allergy and Rheumatology 1990-1995

UNC Health Sciences Library Advisory Committee 1987-1994

North Carolina Tripartite Committee 1989-1993

Advisor, Student Branches NCPHA, APhA (North Carolina) 1986-1993

UNC Honors Program Committee 1987-1990

Chairman 1988

UNC Faculty Fellows Program 1988-1989

Basic Cardiac Life Support Instructor, American Heart Association 1983-1987

Field Editor, ASHP Signal-Ambulatory Care 1986

Editor, OCCHS Clinical Newsletter 1984-1985

President, PharmD. Class of 1982, University of Kentucky

Student Advisory Committee, University of Kentucky College of Pharmacy 1976-1977, 1980-1981

Voluntary Faculty Member, University of Kentucky - 1978-1980

College of Pharmacy Dean's List - 1980

Member, KPhA Health and Welfare Committee - 1977

SAKPhA Delegate, KPhA House of Delegates - 1977

Vice-President, Rho Chi Honor Society - 1977

Chapter Delegate, Kappa Psi Province 5 Convention - 1977

Social Chairman, College of Pharmacy - Class of 1977

Treasurer, Kappa Psi Pharmaceutical Fraternity - 1976

President, Student American-Kentucky Pharmaceutical Association - 1976